Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) is a Healthcare company (Biotechnology) with a market capitalization of $57M. The Maz Rating grades it against the other companies in its sector.
Tonix Pharmaceuticals Holding Corp.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $2.94, Tonix Pharmaceuticals Holding Corp. trades at 1.3x sales and 0.3x book value. Over the last twelve months it generated about $43M of revenue and a net loss of $242M. It runs a gross margin of 86.9%, an operating margin of -436.3% and a net margin of -420.4%. It shows return on equity of -81.0%, return on invested capital of -93549.8% and a free cash flow yield of -297.6%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 4.57. Over the past 52 weeks the share price ranged from $2.81 to $20.56, with a beta of 1.90.
Tonix Pharmaceuticals Holding Corp. does not currently pay a dividend.
7 Wall Street analyst ratings cover the stock: 6 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and diagnostic tools, all aimed at combating human illnesses and easing patient discomfort. The company boasts a comprehensive pipeline of potential treatments spanning several key medical fields: immunology, rare conditions, infectious diseases, and central nervous system (CNS) disorders. In the realm of immunology, Tonix is progressing with biologics designed to address organ transplant rejection, various autoimmune diseases, and certain forms of cancer. A prominent candidate here is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, which is being investigated for its utility in preventing both allograft and xenograft rejection, as well as in treating autoimmune disorders. Its rare disease initiatives include TNX-2900, a specific treatment candidate for Prader-Willi syndrome. The infectious disease segment features a diverse array of programs: TNX-801, a vaccine designed to offer protection against smallpox and monkeypox. TNX-1840 and TNX-1850, which are live virus vaccines based on the company's recombinant pox vaccine (RPV) platform, targeting COVID-19. TNX-3500, a small molecule antiviral drug for the treatment of acute COVID-19. TNX-102 SL, a small molecule medication under investigation for Long COVID, a persistent post-acute COVID-19 condition. Finally, the CNS portfolio encompasses both small molecules and biologics intended to manage pain, neurological conditions, psychiatric ailments, and addiction. Notably, TNX-102 SL is also in mid-Phase 3 development for alleviating fibromyalgia symptoms. Other CNS candidates include TNX-1900, which is being developed to prevent migraine headaches, and TNX-1300, a biologic aimed at treating cocaine intoxication. The company was established in 2007 and maintains its headquarters in Chatham, New Jersey.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Tonix Pharmaceuticals Holding Corp. (TNXP) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 0.11% / 30% · Interest income / Revenue 7.90% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 0.11% / 33% · Receivables / Mkt Cap (36m) 0.01% / 49% · Interest income / Revenue 7.90% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 0.11% / 33.33% · Receivables / Mkt Cap (24m) 0.01% / 33.33% · Interest income / Revenue 7.90% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.16% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 72.1% / 33.33% · Receivables / Avg Assets (4Q) 3.85% / 33.33% · Interest income / Revenue 7.90% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 67.2% / 33.33% · (Cash+Recv) / Total Assets 73.2% / 33.33% · Interest income / Revenue 7.90% / 5% | Fail |
No. As of September 2026, Tonix Pharmaceuticals Holding Corp. (TNXP) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Tonix Pharmaceuticals Holding Corp. is over the AAOIFI limit on Interest income / Revenue.
About 7.90% of each dividend: Tonix Pharmaceuticals Holding Corp.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.